A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

Diabetes Care

Volumn 22, Issue 6, 1999, Pages 960-964

  Holman, Rury R ^a   Cull, Carole A ^a   Turner, Robert C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ACARBOSE; ALBUMINURIA; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; TIME FACTORS; TRISACCHARIDES;

EID: 0033046464     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.6.960     Document Type: Article

References (12)

1. UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
2. UKPDS Group: UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
3. UKPDS Group: UK Prospective Diabetes Study 16: Overview of six years' therapy of type 2 diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
4. UKPDS Group: UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
5. Hillebrand I: Pharmacological modification of digestion and absorption. Diabet Med 4:147-150, 1987
6. Coniff RF, Shapiro JA, Seaton TB, Bray GA: Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin dependent diabetes mellitus. Am J Med 98:443-451, 1995
7. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928-935, 1994
8. UKPDS Group: UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877-890, 1991
9. UKPDS Group: UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544, 1994
10. SAS Institute: Statistical Analysis System, 6th ed. Gary, NC, SAS Institute, 1990
11. Turner RC, Levy JC, Rudenski AS, Hammersley M, Page R: Measurement of insulin resistance and beta-cell function: the HOMA and CIGMA approach. In Current Topics in Diabetes Research. Belfiore F, Bergman RN, Molinatti GM, Eds. Basel, Karger, vol. 12. 1993, p. 66-75
12. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193, 1996